Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLMDGalmed Pharmaceuticals$0.73+7.4%$0.63$0.41▼$2.34$4.00M0.731.82 million shs75,521 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLMDGalmed Pharmaceuticals-1.61%+9.68%+19.07%+7.94%-54.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLMDGalmed Pharmaceuticals$0.73+7.4%$0.63$0.41▼$2.34$4.00M0.731.82 million shs75,521 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLMDGalmed Pharmaceuticals-1.61%+9.68%+19.07%+7.94%-54.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLMDGalmed Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest GLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GLMDGalmed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$2.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLMDGalmed Pharmaceuticals-$10.31M-$1.24N/AN/AN/AN/A-29.43%-26.00%7/30/2026 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLMDGalmed PharmaceuticalsN/A6.556.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLMDGalmed Pharmaceuticals76.14%Insider OwnershipCompanyInsider OwnershipGLMDGalmed Pharmaceuticals19.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLMDGalmed Pharmaceuticals205.48 million4.39 millionNot OptionableGLMD HeadlinesRecent News About These CompaniesTissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac FibrosisJune 2 at 7:30 AM | prnewswire.comGalmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average - Should You Sell?May 29, 2026 | americanbankingnews.comGalmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mgMay 14, 2026 | prnewswire.comTissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based TherapeuticsMay 6, 2026 | prnewswire.comGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest UpdateApril 25, 2026 | defenseworld.netDGalmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain CancersApril 14, 2026 | prnewswire.comGLMD stock shot up 85% pre-market after rising 27% in 5 days – what’s the latest on its Parkinson’s disease therapy?April 9, 2026 | msn.comGalmed Stock Soars On Brain-Penetrating Aramchol FormulationApril 9, 2026 | benzinga.comGalmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, AramcholApril 9, 2026 | prnewswire.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025March 31, 2026 | prnewswire.comGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationJanuary 31, 2026 | finanznachrichten.deGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationJanuary 30, 2026 | prnewswire.comGalmed Pharmaceuticals’ Aramchol study: Key updates and market implicationsDecember 14, 2025 | msn.comGalmed Pharmaceuticals’ Aramchol abstract accepted for HEP-DART 2025 presentationDecember 9, 2025 | msn.comGalmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 MeetingDecember 8, 2025 | prnewswire.comGalmed stock rises after patent grant for MASH combo therapyDecember 4, 2025 | za.investing.comGalmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASHDecember 4, 2025 | prnewswire.comGalmed Pharmaceuticals stock rises on CEO’s optimistic outlookDecember 2, 2025 | za.investing.comGalmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive UpdateDecember 2, 2025 | msn.comGalmed Issues CEO Letter to ShareholdersDecember 1, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLMD Company DescriptionsGalmed Pharmaceuticals NASDAQ:GLMD$0.73 +0.05 (+7.37%) Closing price 04:00 PM EasternExtended Trading$0.72 -0.01 (-1.66%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
